ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

被引：0
|
作者：
J. A. Kyte
A. Røssevold
R. S. Falk
B. Naume
机构：
[1] Oslo University Hospital,Department of Clinical Cancer Research
[2] Oslo University Hospital,Department of Cancer Immunology
[3] Oslo University Hospital,Department of Oncology
[4] Oslo University Hospital,Oslo Centre for Biostatistics and Epidemiology
[5] University of Oslo,Institute of Clinical Medicine
来源：
Journal of Translational Medicine | / 18卷
关键词：
Breast cancer; Triple negative; Immunotherapy; Checkpoint inhibitor; Immunogenic cell death; PD-1; PD-L1; Anthracycline; Cyclophosphamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
    Kyte, J. A.
    Rossevold, A.
    Falk, R. S.
    Naume, B.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [2] ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
    J. A. Kyte
    N. K. Andresen
    H. G. Russnes
    S. Ø. Fretland
    R. S. Falk
    O. C. Lingjærde
    B. Naume
    Journal of Translational Medicine, 18
  • [3] ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
    Kyte, J. A.
    Andresen, N. K.
    Russnes, H. G.
    Fretland, S. O.
    Falk, R. S.
    Lingjaerde, O. C.
    Naume, B.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [4] Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study
    Wang, Cheng
    Yuan, Long
    Wu, Xiujuan
    Wang, Yan
    Tian, Hao
    Zhang, Guozhi
    Wan, Andi
    Xiong, Siyi
    Wang, Chengfang
    Zhou, Yuqin
    Ma, Dandan
    Bao, Yangqiu
    Qu, Man
    Jiang, Jun
    Zhang, Yi
    Qi, Xiaowei
    BMC MEDICINE, 2024, 22 (01):
  • [5] Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer
    Philipovskiy, Alexander
    Chambers, Karinn
    Konstantinidis, Ioannis
    McCallum, Richard
    Corral, Javier
    Gaur, Sumit
    IMMUNOTHERAPY, 2020, 12 (18) : 1293 - 1302
  • [6] Efficacy and Safety of Atezolizumab Monotherapy or Combined Therapy with Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Alimohammadi, Mina
    Faramarzi, Fatemeh
    Mafi, Alireza
    Mousavi, Tahoora
    Rahimi, Ali
    Mirzaei, Hamed
    Asemi, Zatollah
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (31) : 2461 - 2476
  • [7] IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer
    Cortes, Javier
    Andre, Fabrice
    Goncalves, Anthony
    Kuemmel, Sherko
    Martin, Miguel
    Schmid, Peter
    Schuetz, Florian
    Swain, Sandra M.
    Easton, Valerie
    Pollex, Erika
    Deurloo, Regula
    Dent, Rebecca
    FUTURE ONCOLOGY, 2019, 15 (17) : 1951 - 1961
  • [8] Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial
    Montagna, Emilia
    Bagnardi, Vincenzo
    Cancello, Giuseppe
    Sangalli, Claudia
    Pagan, Eleonora
    Iorfida, Monica
    Mazza, Manuelita
    Mazzarol, Giovanni
    Dellapasqua, Silvia
    Munzone, Elisabetta
    Goldhirsch, Aaron
    Colleoni, Marco
    BREAST CARE, 2018, 13 (03) : 177 - 181
  • [9] A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer
    Blum, Joanne L.
    Goncalves, Anthony
    Efrat, Noa
    Debled, Marc
    Conte, Pierfranco
    Richards, Paul D.
    Richards, Donald
    Lardelli, Pilar
    Nieto, Antonio
    Cullell-Young, Martin
    Delaloge, Suzette
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (02) : 295 - 302
  • [10] Capecitabine metronomic chemotherapy combined with autologous CIK cell immunotherapy in the treatment of recurrent and metastatic triple-negative breast cancer
    Chen, Sipan
    Yang, Yaobo
    Jiao, Yang
    Sun, Hua
    Yan, Zhaoyong
    JOURNAL OF BUON, 2021, 26 (03): : 734 - 740
12345